Characteristic |
Prognostic Factor |
Studies Indicating an Association and Quality |
Strength of Association with Tumor Response |
Strength of Association with Survival |
---|---|---|---|---|
Performance status |
Poor vs. good performance status at baseline |
Heinrich, et al., 2003 Verweij, et al., 2004 |
HR: 1.57 (1.18-2.1) No significant relationship |
HR: 2.8 (1.57-5.02) |
Dose of imatinib |
600 mg vs. 400 mg dose |
Heinrich, et al., 2003 |
HR: 0.57 (0.36-0.91) |
|
Creatinine |
Elevated creatinine at baseline vs. not elevated |
Heinrich, et al., 2003 |
HR: 2.9 (0.86-9.80) |
|
Prior chemotherapy |
Prior chemotherapy vs. no prior chemotherapy |
Heinrich, et al., 2003 |
HR: 2.6 (0.98-7.06) |
Abbreviations: PET = FDG positive emission tomography; CT = computed tomography; TTP = time to progression; OS = overall survival; EFS = event free survival; HR = hazard ratio; RECIST = RECIST response criteria—go to Table 2; NS = not significant
*In this study hazard rations greater than one are predictive of poorer prognosis.